iBio, Inc.: iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the developme ...
iBio, AstralBio announce development of antibody inhibiting Activin E
Bio (IBIO) in collaboration with AstralBio announced the development of an antibody that inhibits the function of Activin E, a promising ...
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
Achievement strengthens iBio’s partnered cardiometabolic and obesity program while showcasing its proprietary AI-driven drug ...
BioWorld2d
Ibio licenses long-acting anti-myostatin antibody from Astralbio
Ibio Inc. has expanded its cardiometabolic and obesity treatment development program by in-licensing a long-acting anti-myostatin antibody from Astralbio Inc. The antibody, now named IBIO-600, was ...
FierceBiotech6d
iBio pens $29M biobucks deal with AstralBio for obesity med designed to preserve muscle mass
San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...
Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform
On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a ...
iBio expands cardiometabolic, obesity treatment development program
Bio (IBIO) announced the expansion of its cardiometabolic and obesity treatment development program by in-licensing a potentially ...
manilatimes7d
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific ...
manilatimes7d
Anfield Energy Inc. Provides Further Update on Proposed Plan of Arrangement
The Company has also received notice from UEC that it has extended its offer to subscribe for 107,142,857 common shares of ...
Nasdaq23d
iBio initiated with a Buy at Lucid Capital
The firm says iBio is advancing its partnered anti-myostatin program with AstralBio, targeting cardiometabolic diseases such as obesity. TipRanks is the most comprehensive data set of sell side ...